Owlstone Medical
On a mission to improve non-invasive diagnostics and precision medicine for cancer, respiratory diseases, liver diseases, digestive health and more, the company’s sensitive Breath Biopsy device is designed to discover and validate novel non-invasive breath biomarkers of disease.
Its award-winning ReCIVA Breath Sampler ensures that breath samples containing volatile organic compounds (VOCs) are reliably collected. The VOCs are then analysed using advanced chemical analysis technologies.
Owlstone recently secured $6.5m from the Bill & Melinda Gates Foundation. In September 2024, Owlstone secured a five-year Research Collaboration Agreement is with the FDA’s Center for Devices and Radiological Health – Office of Science and Engineering Laboratories to develop methods for the confident identification of individual chemicals in the complex mixture of breath.
